on SENSORION (EPA:ALSEN)
Sensorion to Present at J.P. Morgan Healthcare Conference
Sensorion, a biotechnology company specializing in therapies for hearing loss disorders, will participate in the 44th Annual J.P. Morgan Healthcare Conference. This event will take place in San Francisco, USA, from January 12-15, 2026. Sensorion's CEO, Nawal Ouzren, is set to present on January 15 at 8:15 AM PT, followed by a Q&A session.
Sensorion is a clinical-stage company focusing on novel treatments for hearing loss, addressing an unmet global medical need. Its pipeline includes gene therapy programs for deafness caused by genetic mutations, developed with Institut Pasteur. The company is progressing with SENS-401, a small molecule drug in Phase 2 trials, aimed at preventing hearing loss.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all SENSORION news